The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

Only 31% of patients with prostate cancer receiving radiation therapy had a successful CT simulation on the first attempt, while more than half required multiple scans on the same day and nearly 17% ...

New findings out of VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine show that an innovative drug effectively prevents prostate tumors from spreading to an advanced ...